Carven P C, Morrelli H F
West J Med. 1975 Mar;122(3):277-8.
This statement was prepared in response to a request made to the Clinical Pharmacology Service at the University of California, San Francisco to evaluate the potential therapeutic uses and the possible toxicities of chelation therapy. The question arose in regard to the use of ethylene tetraacetic acid (EDTA) in the treatment of atherosclerotic cardiovascular disease.
本声明是应向加利福尼亚大学旧金山分校临床药理服务部提出的一项请求而编写的，该请求旨在评估螯合疗法的潜在治疗用途和可能的毒性。关于使用乙二胺四乙酸（EDTA）治疗动脉粥样硬化性心血管疾病的问题由此产生。
